Tag Archives: BPD

Towards Photodynamic Image-Guided Surgery of Head and Neck Tumors: Photodynamic Priming Improves Delivery and Diagnostic Accuracy of Cetuximab-IRDye800CW

June 28, 2022 by Modulight
No comments
Published in: Frontiers in Oncology Authors: Chanda Bhandari, John Fakhry, Menitte Eroy, Jane Junghwa Song, Kimberley Samkoe, Tayyaba Hasan, Kenneth Hoyt, Girgis Obaid    Published in: Frontiers in Oncology Authors: Chanda Bhandari, John Fakhry, Menitte Eroy, Jane Junghwa Song, Kimberley Samkoe, Tayyaba Hasan, Kenneth Hoyt, Girgis Obaid   The study showed that photodynamic priming (subtherapeutic doses of light using ML6500) of tumor microenvironment with nanoliposomal BPD is highly beneficial for delivery of antibodies (Cet-IR800) to H&N tumor in mice. Priming significantly improved the tumor accumulation of Cet-IR800 and diagnostic accuracy of tumor detection, as monitored with fluroescence imaging.   Read the article here

Light penetration depth in brain with different photosensitizers

October 28, 2021 by Modulight Content
No comments
  Motivation for the study Glioblastoma is the most aggressive and lethal brain cancer with an average prognosis of 15 months. Fluorescence-guided surgery (FGS) for glioblastoma was FDA-approved in 2017, while photodynamic therapy (PDT) remains an active area of clinical investigation with very promising results so far. The aim of PDT is to eradicate the invasive cancer cells within 2 cm of the resected area where the glioblastoma most often recurs. However, a significant hurdle of this therapy modality is the limited light penetration depth Continue reading →Customer case Research by: University of Maryland, Optical Therapeutics & Nanotechnology Laboratory led by Prof. Huang. Research focuses on precision cancer nanomedicine, drug delivery strategies, overcoming cancer resistance, mechanism-based combination therapies, site-directed photochemistry and fluorescence diagnostics. Modulight has started a joint R&D program with Dr. Huang lab to study novel EGFR-targeted combination therapy/diagnostic agent PIC-Nal-IRI developed by Huang lab. Modulight products: ML6600 laser system (635 nm and 689 nm). Professor Huang-Chiao Huang Laser use: Targeted photodynamic therapy/photoimmunotherapy with benzoporphyrin derivative (BPD) & 5-aminolevulinic acid (5-ALA) photosensitizers. Continue reading →

Breaking the selectivity‑uptake trade‑off of photoimmunoconjugates with nanoliposomal irinotecan for synergistic multi‑tier cancer targeting

January 2, 2020 by Modulight
No comments
Published in: Journal of Nanobiotechnology Authors: Barry J. Liang, Michael Pigula, Yan Baglo, Daniel Najafali , Tayyaba Hasan, Huang‑Chiao Huang    Published in: Journal of Nanobiotechnology Authors: Barry J. Liang, Michael Pigula, Yan Baglo, Daniel Najafali , Tayyaba Hasan, Huang‑Chiao Huang   The ML6600 laser was used to test the PDT efficacy of a novel photoimmunoconjugate-nanoliposome (PIC-Nal) comprising of EGFR-targeted Cetuximab, BPD photosensitizer and irinotecan chemoterapy inside a liposome. Different cancer cell lines were used and cell viability was determined after PDT.   Read the article here

Porphyrin-lipid assemblies and nanovesicles overcome ABC transporter-mediated photodynamic therapy resistance in cancer cells

August 10, 2019 by Modulight
No comments
Published in: Cancer Letters Authors: Yan Baglo, Barry J. Liang, Robert W. Robey, Suresh V. Ambudkar, Michael M. Gottesman, Huang-Chiao Huang    Published in: Cancer Letters Authors: Yan Baglo, Barry J. Liang, Robert W. Robey, Suresh V. Ambudkar, Michael M. Gottesman, Huang-Chiao Huang   They have used laser to study PDT resistance mechanisms by activating BPD photosensitizer in cancer cell lines and subsequently determining the cell viabilities. The lipidation of BPD is shown to decrease its efflux from cells and increase PDT effectiveness.   Read the article here